Related Experiment Video
Updated: Feb 28, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Targeting low-grade inflammation in multiple sclerosis through the Wim Hof method or lifestyle intervention: a pilot
Darina Slezáková1, Louise Mária Sabolová1, Peter Marček1
1Second Department of Neurology, Faculty of Medicine, Comenius University, University Hospital in Bratislava, Bratislava, Slovakia.
Background:
Disease-modifying therapies (DMTs) in multiple sclerosis (MS) effectively reduce relapse activity but have limited impact on chronic progression and neurodegeneration. Non-pharmacological interventions such as structured exercise or the Wim Hof Method (WHM- which includes breathing exercises, cold exposure, and meditation), may offer complementary immunomodulatory and neuroprotective benefits.
Objectives:
To compare the effects of WHM and a lifestyle intervention (LIFE; structured physical activity and nutritional counseling) on systemic inflammation and neurodegeneration biomarkers in patients with MS.
Methods:
In this randomized, prospective pilot trial, 60 MS patients (2017 McDonald criteria, EDSS 1.0-5.5) were allocated to WHM, LIFE, or control (CTRL) for 12 weeks. Serum cytokines (IFN-γ, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were assessed at baseline and after 12 weeks. Mixed repeated-measures ANOVA with Bonferroni correction was applied.
Results:
Complete datasets were obtained and analyzed for 43 participants (12 WHM, 17 LIFE, 14 CTRL; power= 0.81). Both interventions significantly reduced IL-17A and IL-18 (p<0.001), indicating attenuation of Th17-related inflammation. WHM further decreased IFN-γ, while LIFE lowered IL-8. No significant changes were observed for IL-1β, IL-6, IL-12p70, NfL, or GFAP. Both interventions were well tolerated, with no treatment-related adverse events.
Conclusions:
Both WHM and lifestyle modification demonstrated comparable short-term anti-inflammatory effects in MS, supporting their safety and feasibility as adjunctive strategies to DMT. Although neurodegeneration biomarkers remained unchanged, the consistent reduction of IL-17A and IL-18 highlights their potential to modulate smoldering inflammation. Larger, longer-term trials are warranted to determine their sustained effects on disease progression.
More Related Videos
08:05Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
Published on: March 1, 2017
16:13Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro
Published on: June 13, 2011